YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs
The drug distributor for pharmacies and community-level medical institutions has filed for a Hong Kong listing, boasting strong revenue growth but also massive losses Key Takeaways: YSB has filed for…
RELATED ARTICLES
-
Slowing revenue growth hurts online drug platform YSB
9885.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Inaugural operating profit fails to lift 111 Inc.
YI.US
- Bayzed joins IPO quest as medical rivalry heats up
-
Third time’s the charm: Fangzhou finally finds winning tonic for Hong Kong IPO
6086.HK
